未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumorsI期研究：XNW27011（一种新型 Claudin 18.2 抗体偶联药物）在局部晚期和/或转移性实体瘤患者中的研究
Yu, J.; Sun, Y.; Liu, T.; Gao, S. G.; Guo, Z.; Liang, X.; Ning, F.; Zhang, M.; Zhang, Y.; Zhang, N.; Wang, X.; Zhao, H.; Hu, Y.; Wei, H.; Zhao, Y.; Wang, Y.; Shi, Q.; Li, J. 分享 收藏 Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trialPlinabulin/docetaxel与docetaxel在铂类方案后2L/3L EGFR野生型NSCLC中的生存获益比较（DUBLIN-3）：一项随机III期试验Feinstein, T. M.; Han, B.; Shi, Y-K.; Chen, G.; Yao, Y.; Hu, C.; Shi, J.; Feng, J.; Wu, H.; Cheng, Y.; Guo, Q.; Jie, Z.; Ye, F.; Zhang, Y.; Liu, Z.; Mao, W. D.; Bazhenova, L.; Wu, Y.; Huang, L.; Sun, Y. 分享 收藏 Combined Chemotherapy and Immunotherapy Induction for Screening of Patients with Cervical Esophageal Carcinoma for Subsequent Local Treatment: A New Treatment Paradigm (Jul 26, 10.1245/s10434-024-15843-3, 2024)Dai, Liang; Wu, Ya-Ya; Sun, Yan; Yu, Rong; Yan, Wan-Pu; Yang, Yong-Bo; Cheng, Hong; Gao, Yi-Mei; Zhang, Bin; Chen, Ke-Neng 分享 收藏 Combined Chemotherapy and Immunotherapy Induction for Screening of Patients with Cervical Esophageal Carcinoma for Subsequent Local Treatment: A New Treatment ParadigmDai, Liang; Wu, Ya-Ya; Sun, Yan; Yu, Rong; Yan, Wan-Pu; Yang, Yong-Bo; Cheng, Hong; Gao, Yi-Mei; Zhang, Bin; Chen, Ke-Neng 分享 收藏 Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiotaZhang, Haonan; Shi, Yulu; Lin, Chanchan; He, Chengcheng; Wang, Shanping; Li, Qingyuan; Sun, Yan; Li, Mingsong 分享 收藏 RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine plus cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)Yang, Y.; Pan, J.; Wang, H.; Qu, S.; Chen, N.; Chen, X.; Sun, Y.; He, X.; Hu, C.; Lin, L.; Yu, Q.; Wang, S.; Wang, G.; Lei, F.; Wen, J.; Yang, K.; Lin, Z.; Wu, Y.; Fang, W.; Zhang, L. 分享 收藏 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer泛亚适应ESMO临床实践指南，用于局部结肠癌患者的诊断治疗和随访Yoshino, T.; Argiles, G.; Oki, E.; Martinelli, E.; Taniguchi, H.; Arnold, D.; Mishima; Li, Y.; Smruti, B. K.; Ahn, J. B.; Faud, I.; Chee, C. E.; Yeh, K. -h.; Lin, P. -c.; Chua, C.; Hasbullah, H. H.; Lee, M. A.; Sharma, A.; Sun, Y.; Curigliano, G.; Bando, H.; Lordick, F.; Yamanaka, T.; Tabernero, J.; Baba, E.; Cervantes, A.; Ohtsu, A.; Peters, S.; Ishioka, C.; Pentheroudakis, G. 分享 收藏 分享 收藏 First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial化疗联合西妥昔单抗一线治疗中国头颈部复发和/或转移性鳞状细胞癌患者: 随机III期CHANGE-2试验的疗效和安全性结果Guo, Ye; Luo, Yi; Zhang, Qingyuan; Huang, Xiaoming; Li, Zhengdong; Shen, Liangfang; Feng, Jifeng; Sun, Yan; Yang, Kunyu; Ge, Minghua; Zhu, Xiaodong; Wang, Lin; Liu, Yanyan; He, Xiaohui; Bai, Chunmei; Xue, Kai; Zeng, Yan; Chang, XinYing; Chen, Wenfeng; Lin, Tongyu 分享 收藏 分享 收藏 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated resultsChen, X.; Hu, C.; Wang, W.; Zou, Q.; Li, J.; Lin, Q.; Zhu, X.; Jiang, Y.; Sun, Y.; Shen, L.; Wang, L.; Zou, G.; Lin, X.; Wang, Y.; Lin, S.; Li, M.; Ao, R.; Xu, R.; Lin, H.; Wang, R. 分享 收藏 Nutrition Impact Symptom Clusters in Patients With Head and Neck Cancer Receiving Concurrent Chemoradiotherapy营养对头颈部肿瘤同步放化疗患者症状群的影响Wang, Yujie; Lu, Qian; Zhang, Lichuan; Zhuang, Bing; Zhang, Tong; Jin, Sanli; Sun, Yan; Xiao, Shaowen; Zheng, Baomin; Fang, Yu; Gong, Liqing; Wang, Yanli; Cao, Yiwei; Wang, Weihu 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
